Schizophrenia Clinical Trial
Official title:
Qualitative Study Among Relatives of Patients With Schizophrenia: Experience, Expectations and Impact of the Diagnostic Announcement
The diagnostic announcement of a chronic disorder is an essential step in the patient's care.
Recommendations specify the importance of including caregivers at the time of the
announcement. In practice, caregivers are not systematically associated with the announcement
of the diagnosis of schizophrenia, while the daily support of patients is provided in 75% of
cases by the family. This support can lead to the exhaustion of caregivers and have
repercussions on their sick loved one.
This study will qualitatively describe and explore the experience of the diagnostic
announcement in relatives of patients with schizophrenia. Specifically, the investigators
will explore the history before the diagnosis is announced, the conditions of the
announcement and the experiences of relatives as well as the impact at the personal and
family-levels. This study will also explore the expectations of caregivers and avenues for
reflection for announcement of schizophrenia diagnosis.
The number of subjects to be included in this study is therefore set at 30. A preselection of
each potential participant will be carried out by phone or in person to ensure the presence
of inclusion criteria and the absence of non-inclusion criteria. The patients will also be
provided with oral information about the study to allow sufficient time to reflect before
inclusion. Then, the selection-inclusion-interview visit will take place visually in an
intra-hospital or extra-hospital consultation structure of the Center Hospitalier
Alpes-Isère. This visit will be unique and will consist of the entire protocol. It will be
both a selection, inclusion and interview visit.
Once the results have been analyzed, this study will provide a better understanding of the
experiences of relatives of patients when the diagnosis of schizophrenia is announced, the
impact of this announcement on caregivers and family relationships and the expectations of
caregivers regarding this announcement. In the long term, the data collected will be add
value in developing medical recommendations on consultation to announce the diagnosis of
schizophrenia to relatives of patients, in order to best meet the expectations of relatives
and to minimize as much as possible the harmful impact that can have such announcement.
Schizophrenia is a psychiatric disorder that affects 1% of the population worldwide. The
diagnostic announcement of this chronic disorder is an essential step in the patient's care.
Recommendations specify the importance of including caregivers at the time of the
announcement. In practice, caregivers are not systematically associated with the announcement
of the diagnosis of schizophrenia, while the daily support of patients is provided in 75% of
cases by the family. This support can lead to the exhaustion of caregivers and have
repercussions on their sick loved one.
This study will qualitatively describe and explore the experience of the diagnostic
announcement in relatives of patients with schizophrenia. Specifically, the investigators
will explore the history before the diagnosis is announced, the conditions of the
announcement and the experiences of relatives as well as the impact at the personal and
family-levels. This study will also explore the expectations of caregivers and avenues for
reflection for announcement of schizophrenia diagnosis.
The number of subjects to be included in this study is therefore set at 30. A preselection of
each potential participant will be carried out by phone or in person to ensure the presence
of inclusion criteria and the absence of non-inclusion criteria. The patients will also be
provided with oral information about the study to allow sufficient time to reflect before
inclusion. Then, the selection-inclusion-interview visit will take place visually in an
intra-hospital or extra-hospital consultation structure of the Center Hospitalier
Alpes-Isère. This visit will be unique and will consist of the entire protocol. It will be
both a selection, inclusion and interview visit.
Once the results have been analyzed, this study will provide a better understanding of the
experiences of relatives of patients when the diagnosis of schizophrenia is announced, the
impact of this announcement on caregivers and family relationships and the expectations of
caregivers regarding this announcement. In the long term, the data collected will be add
value in developing medical recommendations on consultation to announce the diagnosis of
schizophrenia to relatives of patients, in order to best meet the expectations of relatives
and to minimize as much as possible the harmful impact that can have such announcement.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |